The Way Forward: Translation (Q60358611)

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Translating advances from the basic biology of aging into clinical application

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

In search of Methuselah: estimating the upper limits to human longevity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Single-gene mutations and healthy ageing in mammals

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Exceptional parental longevity associated with lower risk of Alzheimer's disease and memory decline

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Clinical strategies and animal models for developing senolytic agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Rapamycin fed late in life extends lifespan in genetically heterogeneous mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Metformin improves healthspan and lifespan in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

The Achilles' heel of senescent cells: from transcriptome to senolytic drugs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and enhancing NMDA signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

The caloric restriction paradigm: implications for healthy human aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Rejuvenation of aged progenitor cells by exposure to a young systemic environment

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Muscle-derived stem/progenitor cell dysfunction limits healthspan and lifespan in a murine progeria model

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Cellular senescence and the senescent secretory phenotype: therapeutic opportunities

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Rapamycin: one drug, many effects

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Rapalogs and mTOR inhibitors as anti-aging therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Drugs that modulate aging: the promising yet difficult path ahead

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Rapamycin slows aging in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

How longevity research can lead to therapies for Alzheimer's disease: The rapamycin story

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

mTOR inhibition improves immune function in the elderly

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

The influence of age on the effects of lifestyle modification and metformin in prevention of diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Metformin slows down aging and extends life span of female SHR mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Metformin supplementation and life span in Fischer-344 rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Metformin retards aging in C. elegans by altering microbial folate and methionine metabolism.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Control of gluconeogenesis by metformin: does redox trump energy charge?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Caveolin‐1 is essential for metformin inhibitory effect on IGF1 action in non‐small‐cell lung cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Effect of metformin on IGF-1 and IGFBP-1 levels in obese patients with polycystic ovary syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Metformin decreases IGF1-induced cell proliferation and protein synthesis through AMP-activated protein kinase in cultured bovine granulosa cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Metformin and cancer occurrence in insulin-treated type 2 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Increased risk of cognitive impairment in patients with diabetes is associated with metformin

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Long-term metformin usage and cognitive function among older adults with diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Effects of acarbose on the acceleration of postprandial hyperglycemia-induced pathological changes induced by intermittent hypoxia in lean mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Acarbose : An Update of its Pharmacology and Therapeutic Use in Diabetes Mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Does dietary sugar and fat influence longevity?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Effect of inhibition of alpha-glucosidase on age-related glucose intolerance and pancreatic atrophy in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Recent insights into the varying activity of estrogens

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Development of 17alpha-estradiol as a neuroprotective therapeutic agent: rationale and results from a phase I clinical study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

A simple and sensitive microtiter plate estrogen bioassay based on stimulation of alkaline phosphatase in Ishikawa cells: estrogenic action of delta 5 adrenal steroids

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Minireview: A plethora of estrogen receptors in the brain: where will it end?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Emerging models and paradigms for stem cell ageing

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

The relationship between adipose tissue and bone metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Senescence-messaging secretome: SMS-ing cellular stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

The number of p16INK4a positive cells in human skin reflects biological age.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

A biomarker that identifies senescent human cells in culture and in aging skin in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Cellular senescence and the senescent secretory phenotype in age-related chronic diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Growth hormone action predicts age-related white adipose tissue dysfunction and senescent cell burden in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Ink4a/Arf expression is a biomarker of aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Fat tissue, aging, and cellular senescence

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

A crucial role for adipose tissue p53 in the regulation of insulin resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

DNA damage drives accelerated bone aging via an NF-κB-dependent mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Chronic inflammation induces telomere dysfunction and accelerates ageing in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Senescence of activated stellate cells limits liver fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Renal complications of diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Use of Angiotensin Receptor Blockers and the Risk of Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Angiotensin II Receptor Blockers and Risk of Cancer in Patients With Systemic Hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Variations of the angiotensin II type 1 receptor gene are associated with extreme human longevity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Disruption of the Ang II type 1 receptor promotes longevity in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Long-term angiotensin II type 1 receptor blockade with fonsartan doubles lifespan of hypertensive rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Long-term ACE Inhibition Doubles Lifespan of Hypertensive Rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Effects of angiotensin-converting enzyme inhibition on mitochondrial number in the aging mouse

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Protective effect of long-term angiotensin II inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Protective effect of the inhibition of the renin-angiotensin system on aging

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Sir2 mediates longevity in the fly through a pathway related to calorie restriction

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Regulation of Caenorhabditis elegans lifespan by sir-2.1 transgenes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

The sirtuin SIRT6 regulates lifespan in male mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Franklin H. Epstein Lecture: Sirtuins, aging, and medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Sirtuin activators mimic caloric restriction and delay ageing in metazoans

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Resveratrol improves health and survival of mice on a high-calorie diet

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

SRT1720 improves survival and healthspan of obese mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, high-sugar diet.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Small molecule SIRT1 activators for the treatment of aging and age-related diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus--systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Resveratrol and obesity: Can resveratrol relieve metabolic disturbances?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Deleted in Breast Cancer 1 regulates cellular senescence during obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

A nationwide study of aspirin, other non-steroidal anti-inflammatory drugs, and Hodgkin lymphoma risk in Denmark

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

The ancient drug salicylate directly activates AMP-activated protein kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Aspirin extends the lifespan of Caenorhabditis elegans via AMPK and DAF-16/FOXO in dietary restriction pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Adverse events associated with mTOR inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

The basics of preclinical drug development for neurodegenerative disease indications

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Are sirtuins viable targets for improving healthspan and lifespan?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Senescent Cells Contribute to the Physiological Remodeling of Aged Lungs

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Inflammation, coagulation, and the pathway to frailty

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Measuring systemic inflammatory regulation in older adults: evidence and utility

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Upregulated ex vivo expression of stress-responsive inflammatory pathway genes by LPS-challenged CD14( ) monocytes in frail older adults.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Inflammation and stress-related candidate genes, plasma interleukin-6 levels, and longevity in older adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Inflammation and frailty in older women.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Frailty in older adults: evidence for a phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Phenotype of frailty: characterization in the women's health and aging studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Long-Term Risks of Death and Institutionalization of Elderly People in Relation to Deficit Accumulation at Age 70

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Frailty defined by deficit accumulation and geriatric medicine defined by frailty

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

An index of self-rated health deficits in relation to frailty and adverse outcomes in older adults.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Weight loss, exercise, or both and physical function in obese older adults

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Criteria for clinically relevant weakness and low lean mass and their longitudinal association with incident mobility impairment and mortality: the foundation for the National Institutes of Health (FNIH) sarcopenia project

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Autophagy induction by SIRT6 through attenuation of insulin-like growth factor signaling is involved in the regulation of human bronchial epithelial cell senescence.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Accelerated epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF-β-induced senescence of human bronchial epithelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Murine models of pulmonary fibrosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Idiopathic pulmonary fibrosis: evolving concepts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Diabetes and cancer: epidemiology and potential mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Clinical ascertainment of health outcomes among adults treated for childhood cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Frailty in childhood cancer survivors

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

Role of progerin-induced telomere dysfunction in HGPS premature cellular senescence

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19

A three-dimensional human neural cell culture model of Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1007/978-3-319-23246-1_19